Loading…
Nuvectis Pharma, Inc. is projected to rise to $35.69 by 2027, a +66% move from its current price of $21.52. NVCT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $20.52 | $21.53 | $22.60 | +0.07% |
| Aug 3 | $20.13 | $21.55 | $23.07 | +0.13% |
| Aug 4 | $19.84 | $21.56 | $23.44 | +0.20% |
| Aug 5 | $19.59 | $21.58 | $23.76 | +0.26% |
| Aug 6 | $19.38 | $21.59 | $24.05 | +0.33% |
| Aug 7 | $19.20 | $21.60 | $24.31 | +0.39% |
| Aug 8 | $19.03 | $21.62 | $24.56 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.03 | $21.62 | $24.56 | +0.46% |
| Week 2 | $18.13 | $21.72 | $26.01 | +0.92% |
| Week 3 | $17.49 | $21.82 | $27.21 | +1.38% |
| Week 4 | $16.98 | $21.92 | $28.28 | +1.84% |
| Week 5 | $16.56 | $22.02 | $29.28 | +2.31% |
| Week 6 | $16.19 | $22.12 | $30.22 | +2.78% |
| Week 7 | $15.86 | $22.22 | $31.13 | +3.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Nuvectis Pharma, Inc. was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
NVCT is the stock ticker for Nuvectis Pharma, Inc. It is currently priced at $22.76 per share and has a market capitalization of $717.52M, with a market position ranked at 2587.
The 30-day price range runs from $16.57 to $31.26, reflecting notable recent volatility as the stock trades near nearby levels.
Technical indicators show bullish sentiment, with RSI14 at 70, SMA50 at $15.95, and SMA200 at $9.96. The stock sits on a near-term support of $12.59 and a near-term resistance of $28.53. Annualized volatility is 90%.
A major floor 69.4% below — a decisive break under it would weaken the trend.
The nearest floor, 35.8% below — buyers have tended to step in here.
The nearest ceiling, 32.6% above — a clean break opens room to run.
A major ceiling 67.3% above — clearing it would confirm fresh momentum.
Key NVCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.87 | Buy | $21.09 | Buy |
| MA 10 | $20.02 | Buy | $20.43 | Buy |
| MA 20 | $19.46 | Buy | $19.62 | Buy |
| MA 50 | $16.18 | Buy | $16.99 | Buy |
| MA 100 | $12.56 | Buy | $14.13 | Buy |
| MA 200 | $10.04 | Buy | $11.56 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.76 | Neutral |
| Stoch RSI (14) | 58.97 | Neutral |
| CCI (20) | 171.11 | Buy |
| Williams %R (14) | -26.22 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 9.85 | Buy |
| Bollinger %B (20,2) | 0.96 | Neutral |
| Stochastic %K (14) | 73.78 | Neutral |
| TRIX (15) | 0.92 | Buy |
| Awesome (5,34) | 1.78 | Buy |
| Ultimate (7,14,28) | 64.65 | Neutral |
| Momentum (10) | 2.38 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 21.95 | Sell |
| ADX (14) | 19.08 | Neutral |
| ATR (14) | 0.99 | Info |
The near-term technical picture points toward bullish momentum, supported by a 30-day range of $16.57 to $31.26. RSI14 sits at 70, indicating strength in the recent move.
Price dynamics are supported by a 50-day simple moving average of $15.95 and a 200-day simple moving average of $9.96, with a defined near-term support at $12.59 and resistance at $28.53.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.48 | $21.52 | $33.35 | 0% | Neutral | |
| $26.49 | $35.69 | $51.84 | +66% | Bullish | |
| $28.43 | $40.45 | $62.38 | +88% | Bullish | |
| $32.47 | $48.37 | $78.07 | +125% | Bullish | |
| $30.36 | $47.12 | $78.99 | +119% | Bullish | |
| $31.83 | $51.34 | $88.91 | +139% | Bullish | |
| $37.86 | $63.33 | $112.86 | +194% | Bullish | |
| $41.31 | $71.55 | $130.86 | +233% | Bullish | |
| $53.90 | $96.54 | $180.78 | +349% | Bullish | |
| $61.02 | $112.93 | $216.11 | +425% | Bullish | |
| $79.74 | $172.60 | $361.17 | +702% | Bullish | |
| $154.72 | $343.83 | $790.81 | +15.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.48 | $21.52 | $28.10 | +0.00% |
| September 2026 | $19.54 | $23.65 | $29.80 | +9.89% |
| October 2026 | $18.64 | $22.84 | $29.30 | -3.42% |
| November 2026 | $18.77 | $23.23 | $30.24 | +1.71% |
| December 2026 | $20.25 | $25.29 | $33.35 | +8.87% |
Click any year to see its month-by-month NVCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NVCT price prediction for 2026 points to an average of $21.52 (low $7.48, high $33.35) — a potential gain of 0% on today's $21.52. Price action looks broadly range-bound.
In 2027, NVCT is projected to trade between $26.49 and $51.84, averaging $35.69 — a potential gain of +66% from today's $21.52. That is up +66% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Nuvectis Pharma, Inc.'s 2028 outlook centres on $40.45, within a $28.43 to $62.38 range. That is up +13% on the projected 2027 average. That marks a +88% change versus current levels. Momentum favours further upside here.
By 2029, NVCT could reach as high as $78.07, with a base case around $48.37 and support toward $32.47 — roughly +125% from $21.52. Buyers look set to stay in control over this stretch.
Expect NVCT to range from $30.36 to $78.99 through 2030. The $47.12 average target implies a +119% move from current prices. That is -3% versus the projected 2029 average. Momentum favours further upside here.
The NVCT price prediction for 2031 points to an average of $51.34 (low $31.83, high $88.91) — a potential gain of +139% on today's $21.52. Buyers look set to stay in control over this stretch.
In 2032, NVCT is projected to trade between $37.86 and $112.86, averaging $63.33 — a potential gain of +194% from today's $21.52. That is up +23% on the projected 2031 average. Momentum favours further upside here.
Nuvectis Pharma, Inc.'s 2033 outlook centres on $71.55, within a $41.31 to $130.86 range. That is up +13% on the projected 2032 average. That marks a +233% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, NVCT could reach as high as $180.78, with a base case around $96.54 and support toward $53.90 — roughly +349% from $21.52. Momentum favours further upside here.
Expect NVCT to range from $61.02 to $216.11 through 2035. The $112.93 average target implies a +425% move from current prices. That is up +17% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The NVCT price prediction for 2040 points to an average of $172.60 (low $79.74, high $361.17) — a potential gain of +702% on today's $21.52. Momentum favours further upside here.
In 2050, NVCT is projected to trade between $154.72 and $790.81, averaging $343.83 — a potential gain of +15.0x from today's $21.52. That is up +99% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVCT today (≈ 46.468401 NVCT) could be worth
$15,977.16
+$14,977.16 (+1498%) by 2050 · US Dollar
Based on the average projected NVCT price of $343.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVCTwould be worth at today's price.
$1,000 invested in NVCT on Jul 31, 2025 (≈ 143.67816 NVCT) would be worth
$3,091.95
+$2,091.95 (+209.2%) today · 3.09× · US Dollar
Based on a NVCT entry price of $6.96 vs. today's $21.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.31 | $1,114.45 | +11.4% |
| 1 month ago | $19.52 | $1,102.46 | +10.2% |
| 3 months ago | $8.54 | $2,519.91 | +152.0% |
| 6 months ago | $8.36 | $2,574.16 | +157.4% |
| 1 year ago | $6.96 | $3,091.95 | +209.2% |
| All time (4.5y) ago | $3.25 | $6,621.54 | +562.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVCT forecast.
Our base-case forecast reaches $43.00 around 2029.
Implied market cap at $43.00: $1.36B
The multi-year forecast shows a path of rising averages and higher upside, with year-by-year detail as follows. In 2026, the min is $7.48, the avg is $22.76, the max is $35.24, ROI is 0, and sentiment is Neutral.
From 2027 through 2029, the average forecasts are $37.32 (2027), $42.04 (2028), and $49.97 (2029) with maxs of $54.20, $64.81, and $80.63 and ROIs of 64, 84.7, and 119.6 respectively, all with bullish sentiment.
For 2030 the min is $31.16, the avg is $48.36, the max is $81.03, ROI is 112.5, and sentiment is Bullish. The 2031–2035 period continues the bullish trend with 2031 avg $52.54, 2032 $64.51, 2033 $72.40, 2034 $97.57, and 2035 $113.76, with ROIs of 130.9, 183.4, 218.1, 328.7, and 399.8 respectively.
Beyond 2035, the forecast shows 2040 avg $171.77, max $359.22, min $79.45, ROI 654.7, sentiment Bullish, and 2050 avg $338.06, max $777.53, min $152.12, ROI 1385.3, sentiment Bullish. These are estimates, not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows min $31.16, avg $48.36, max $81.03, ROI 112.5, sentiment Bullish.
Forecasts show a bullish path across 2027–2050 with rising averages (e.g., 2027 avg $37.32, 2028 avg $42.04, 2029 avg $49.97, 2030 avg $48.36, 2050 avg $338.06) and positive ROIs (e.g., 64, 84.7, 119.6, 112.5, 1385.3). These figures are estimates, not guarantees.
Yes. The forecast shows max values that exceed $100 in several years: 2035 max $217.58, 2040 max $359.22, and 2050 max $777.53.
Current price is $22.76 and market cap is $717.52M. The rank is 2587.
The near-term setup features a 30-day range of $16.57 to $31.26, with RSI 70, SMA50 $15.95, SMA200 $9.96, support $12.59 and resistance $28.53.
Nuvectis Pharma, Inc. Community Discussion
0Share your Nuvectis Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.